Abstract
Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib “Topase” Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have